 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Lung Function and Death from Chronic Obstructive Pulmonary Disease in
19 February 2002 | Volume 136 Issue 4 | Page I35
1-Antitrypsin MZ Heterozygotes
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Change in Lung Function and Morbidity from Chronic Obstructive Pulmonary Disease in 
1-Antitrypsin MZ Heterozygotes: A Longitudinal Study of the General Population." It is in the 19 February 2002 issue of Annals of Internal Medicine (volume 136, pages 270-279). The authors are M Dahl, A Tybjærg-Hansen, P Lange, J Vestbo, BG Nordestgaard.
What is the problem and what is known about it so far?
Chronic obstructive pulmonary disease (COPD) is a type of lung disease that is usually caused by cigarette smoking. The lungs of people with this disease are progressively destroyed by the irritation caused by cigarette smoke and by infection (bronchitis) that often accompanies smoking. Normal people can usually limit the destructive effects of this irritation because the body manufactures a protein that calms the inflammation caused by irritation from cigarette smoke. This protein (1-antitrypsin) is produced because of the genes that we inherit from our parents. Each parent contributes one copy of the gene to make 1-antitrypsin. Very few people have a total lack of 1-antitrypsin (called 1-antitrypsin deficiency)—meaning that both parents have contributed a defective gene. The totally deficient person is known as a homozygote and is very likely to develop COPD and die at an early age. Many more people have inherited the defective gene from only one parent (heterozygotes). Physicians have been uncertain whether heterozygotes are more likely to develop COPD than are other persons in the normal population.
Why did the researchers do this particular study?
To compare heterozygotes with normal people to find out if they had more COPD, more hospitalizations for COPD, and more deaths from COPD than those who have two copies of the normal gene for 1-antitrypsin.
Who was studied?
9187 people, aged 20 years or older, who were part of the Copenhagen City Heart Study in Denmark.
How was the study done?
Exams were done three times (1976–1978, 1981–1983, and 1991–1994). Participants completed a questionnaire about smoking habits, underwent breathing tests, and had blood drawn during the third exam to see whether they had one copy of the normal 1-antitrypsin gene or two copies.
What did the researchers find?
451 participants (4.9%) had only one copy of the gene for 1-antitrypsin (heterozygotes), and they produced 31% less 1-antitrypsin than normal individuals. Heterozygotes had a slightly faster decline in lung function than genetically normal people. Nineteen percent of heterozygotes had COPD, while 15% of genetically normal participants had COPD. Hospitalization or death from COPD occurred 1.5 times more frequently in heterozygotes than in those with two copies of the normal gene.
What were the limitations of the study?
Approximately one third of the participants had only one breathing test, and their data could not be used to calculate the rate of decline in lung function over time. Blood to test genetic makeup was drawn only during the third examination; because people with more severe lung disease may have dropped out of the study before the third examination, the researchers may not have recorded the genetic makeup of many of these participants.
What are the implications of the study?
People with only one copy of the gene for 1-antitrypsin have an increased risk for developing COPD and are more likely to die of COPD than genetically normal people. Because heterozygotes are much more numerous than are homozygotes, the number of heterozygotes with COPD is about the same as the number of homozygotes.
Related articles in Annals:
1-Antitrypsin MZ HeterozygotesThis article has been cited by other articles:
|
|
 |
|
  M. Zorzetto, E. Russi, O. Senn, M. Imboden, I. Ferrarotti, C. Tinelli, I. Campo, S. Ottaviani, R. Scabini, A. von Eckardstein, et al. SERPINA1 Gene Variants in Individuals from the General Population with Reduced {alpha}1-Antitrypsin Concentrations Clin. Chem., August 1, 2008; 54(8): 1331 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Silva, S. Guerra, S. Keim, R. A. Barbee, and D. L. Sherrill Longitudinal Decline of Diffusing Capacity of the Lung for Carbon Monoxide in Community Subjects With the PiMZ {alpha}1-Antitrypsin Phenotype Chest, May 1, 2008; 133(5): 1095 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brantly Efficient and Accurate Approaches to the Laboratory Diagnosis of {alpha}1-Antitrypsin Deficiency: The Promise of Early Diagnosis and Intervention Clin. Chem., December 1, 2006; 52(12): 2180 - 2181. [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Schwartz and J. C. Ruckdeschel Familial Lung Cancer: Genetic Susceptibility and Relationship to Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 16 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dahl, C. P. Hersh, N. P. Ly, C. S. Berkey, E. K. Silverman, and B. G. Nordestgaard The protease inhibitor PI*S allele and COPD: a meta-analysis Eur. Respir. J., July 1, 2005; 26(1): 67 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Dahl, B G Nordestgaard, and N Seersholm {alpha}1-Antitrypsin genotype unaffected by age * Authors' reply Thorax, March 1, 2005; 60(3): 258 - 259. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. J. Wadsworth, L. E. Vinall, A. L. Jones, R. J. Hardy, D. B. Whitehouse, S. L. Butterworth, W. S. Hilder, J. U. Lovegrove, and D. M. Swallow Alpha1-Antitrypsin as a Risk for Infant and Adult Respiratory Outcomes in a National Birth Cohort Am. J. Respir. Cell Mol. Biol., November 1, 2004; 31(5): 559 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Seersholm Pi MZ and COPD: will we ever know? Thorax, October 1, 2004; 59(10): 823 - 825. [Full Text] [PDF]
|
|
|
|
|
|
C P Hersh, M Dahl, N P Ly, C S Berkey, B G Nordestgaard, and E K Silverman Chronic obstructive pulmonary disease in {alpha}1-antitrypsin PI MZ heterozygotes: a meta-analysis Thorax, October 1, 2004; 59(10): 843 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dahl, A. Tybjaerg-Hansen, P. Schnohr, and B. G. Nordestgaard A Population-based Study of Morbidity and Mortality in Mannose-binding Lectin Deficiency J. Exp. Med., May 17, 2004; 199(10): 1391 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Molfino Genetics of COPD Chest, May 1, 2004; 125(5): 1929 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D L DeMeo and E K Silverman {alpha}1-Antitrypsin deficiency {middle dot} 2: Genetic aspects of {alpha}1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk Thorax, March 1, 2004; 59(3): 259 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Luisetti and N Seersholm {alpha}1-Antitrypsin deficiency {middle dot} 1: Epidemiology of {alpha}1-antitrypsin deficiency Thorax, February 1, 2004; 59(2): 164 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Peppard, T. Young, M. Dahl, A. Tybjaerg-Hansen, B. G. Nordestgaard, P. Lange, J. Vestbo, S. Kony, and M. Zureik Nose and Blood Pressure Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 317 - 319. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dahl, A. Tybjaerg-Hansen, B. G. Nordestgaard, P. J Talmud, R. Wright, G. Steiner, M. Syvanne, and S. E Humphries Risk of Ischemic Heart and Ischemic Cerebrovascular Disease Is not Increased in S, Z, and 11478A {alpha}1-Antitrypsin Carriers of The Copenhagen City Heart Study * Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): e55 - 56. [Full Text]
|
|
|
|
|
|
The pharmacoepidemiology of COPD: Recent advances and methodological discussion Eur. Respir. J., September 1, 2003; 22(43_suppl): 1s - 44s. [Full Text] [PDF]
|
|
|
|
|
|
M. Miravitlles, S. Vila, R. Jardi, C. de la Roza, F. Rodriguez-Frias, and R. Vidal Emphysema due to {alpha}-Antitrypsin Deficiency: Familial Study of the YBARCELONA Variant Chest, July 1, 2003; 124(1): 404 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dahl, A. Tybjaerg-Hansen, H. Sillesen, G. Jensen, R. Steffensen, and B. G. Nordestgaard Blood Pressure, Risk of Ischemic Cerebrovascular and Ischemic Heart Disease, and Longevity in {alpha}1-Antitrypsin Deficiency: The Copenhagen City Heart Study Circulation, February 11, 2003; 107(5): 747 - 752. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
